Solid Performance From Degussa

21 August 1994

German chemical and pharmaceutical company Degussa performed solidly in the first six months of 1994, with pretax profits rising 54% to 186 million Deutschemarks ($119.8 million). Sales were up 1% to 10.9 billion marks ($7.0 billion).

The company said that all its business sectors achieved higher earnings. The pharmaceuticals sector posted sales up 6% to 1.64 billion marks. The company said that around half of this increase was a result of the consolidation of the acquisition of the Dutch dental company Elephant.

Profits of the Asta Medica group increased substantially, mainly as a result of streamlining measures.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight